Author:
Bertsias George,Yazdany Jinoos
Reference9 articles.
1. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial;Navarra;Lancet,2011
2. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus;Furie;Arthritis Rheum,2011
3. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force;van Vollenhoven;Ann Rheum Dis,2014
4. Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting;Gatto;Arthritis Rheumatol,2020
5. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: a real-life, multicentre observational study;Nikoloudaki;Front Immunol,2022